International journal of clinical practice
-
Int. J. Clin. Pract. · Sep 2016
Multicenter Study Comparative Study Observational StudyMajor bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs). ⋯ Among newly anticoagulated NVAF patients in the real-world setting, initiation with rivaroxaban or warfarin was associated with a significantly greater risk of major bleeding compared with initiation on apixaban. When compared with warfarin, initiation with apixaban was associated with significantly lower risk of major bleeding. Additional observational studies are required to confirm these findings.
-
Int. J. Clin. Pract. · Sep 2016
Randomized Controlled Trial Multicenter StudyEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.
Patients with type 2 diabetes mellitus (T2DM) have increased risk of adverse events (AEs; e.g. dehydration, hypoglycaemia) in hot weather. This analysis assessed the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with T2DM who live in hot climates. ⋯ ClinicalTrials.gov NCT01081834, NCT01106677, NCT01106625, NCT01106690, NCT00968812.